Выводы. 
Клинико-экономическое обоснование стратегии определения PCA3 в моче при диагностике рака предстательной железы

Результаты настоящей работы подтверждают высокую диагностическую эффективность исследования экспрессии РСА3 в моче методом ОТ-ПЦР с обратной транскрипцией в режиме реального времени в отношении РПЖ.

Установлено, что прогнозировать степень агрессивности РПЖ на основании уровня экспрессии РСА3 в моче, не представляется возможным.

Продемонстрированы клинические и экономические преимущества определения РСА3 в моче в сравнении с сывороточным ПСА.

Разработана стратегия применения исследования экспрессии PCA3 в постмассажной моче и биоптатах. Предложен диагностический алгоритм, применение которого позволит оптимизировать затраты на раннее выявление РПЖ, за счет сокращения числа ненужных биопсий.

ЛИТЕРАТУРА

• 1. Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol 2012; 3(2):120−9.
• 2. Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol 2015; 26(5):848−64.
• 3. Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2: ERG gene fusion. J Urol. 2012; 187:795−801.
• 4. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975−9.
• 5. Warrick JI, Tomlins SA, Carskadon SL, Young AM, Siddiqui J, Wei JT, et al. Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG. Mod Pathol 2014;27(4):609−20.
• 6. Popa I, Fradet Y, Beaudry G, Hovington Н, Beaudry G, Tetu B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 2007;20:1121−27.
• 7. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8−15.
• 8. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer. Clin Chem 2006;52(6):1089−95.
• 9. Van Gils MP, Hessels D, Van Hooij O, Jannink SA, Peelen WP, Hanssen SL. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin cancer res 2007;13:939−43.
• 10. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009;181(6):2508−13.
• 11. Ng CF, Chiu PKF, Lam NY, Yeung R, Chow J, Chan B. The role of urine prostate cancer antigen 3 mrna levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J 2012;18:459−65.
• 12. Foj L, Milа M, Mengual L, Luque P, Alcaraz A, Jimйnez W, et al. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta 2014;435:53−8.
• 13. Сидоренков А. В., Говоров А. В., Пушкарь Д. Ю., Павлов К. А., Шкопоров А. Н., Хохлова Е. В., и др. Российская тест-система РСА3: первые результаты. Экспериментальная и клиническая урология 2014;2:44−9.
• 14. Wang FB, Chen R, Ren SC, Shi XL, Zhu YS, Zhang W, et al. Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy. Asian J Androl 2016;18:1−6.
• 15. Marks LS, Fradet Y, Lim Deras I, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532−35.
• 16. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, et al. Clinical utility of the PCA3 urine assay in european men scheduled for repeat biopsy. Eur Urol 2008;54:1081−88.
• 17. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587−92.
• 18. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804−09.
• 19. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. PCA3 Urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009;73:363−8.
• 20. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009;115:3879−86.
• 21. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475−81.
• 22. Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 2010;70:1760−7.
• 23. Auprich M, Haese A, Walz J, Pummer K, De La Taille A, Graefen M, et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010;58:727−32.
• 24. Vlaeminck-Guillem V, Campos-Fernandes JL, Champetier D, Chikh K, Decaussin-Petrucci M, Devonec M, et al. Value of PCA3 urinary test for prostate biopsy decision: the lyon-sud university hospital experience. Ann Biol Clin 2011;69:31−9.
• 25. De La Taille A, Irani J, Graefen M, Chun F, De Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011;185:2119−25.
• 26. Pepe P1, Fraggetta F, Galia A, Skonieczny G, Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? Int Braz J Urol 2012;38(4):489−95.
• 27. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort. Anticancer Res 2013;33:553−8.
• 28. Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013;111(6):928−33.
• 29. Charles TPF, Cedex P. Urinary PCA3 urine in patients with a first negative prostate biopsy: 5-year follow-up. Eur Urol 2014;13:347.
• 30. Capoluongo E, Zambon CF, Basso D, Boccia S, Rocchetti S, Leoncini E, et al. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals. Clin Chim Acta 2014;429:46−50.
• 31. Vlaeminck-Guillem V, Devonec M, Champetier D, Decaussi-Petrucci M, Paparel P, Perrin P et al. Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients. Prog Urol 2015;25(16):1160−8
• 32. Merola R, Tomao L, Antenucci A, Sperduti I, Sentinelli S, Masi S, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. Journal of Experimental & Clinical Cancer Research 2015;34(1):15.
• 33. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110:43−9.
• 34. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011;59:422−9
• 35. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70(1):10−6.
• 36. Leyten GHJM, Wierenga EA, Michiel Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, et al. Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. International Journal of Molecular Sciences 2013;14(6):11 347−55.
• 37. Haese A., de la Taille A., van Poppel H., Marberger M., Stenzl A., Mulders P.F., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081−8.
• 38. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008;68:1215−22.
• 39. Nepple K. Сost-analysis of pca3 versus PSA in the detection of prostate cancer in men with a prior negative biopsy. In: Strope S., Kibel A., Sandhu G., Wiegand L., Kymes S, editors. General & Epidemiological Trends & Socioeconomics: Practice Patterns, Cost Effectiveness I. AUA 2012 Annual Meeting. USA. 2012. Abstract № 135.
• 40. Diagnosis and monitoring of prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (PHI). National Institute for Health and Care Excellence, 2014:39−41.
• 41. Аполихин О. И., Сивков А. В., Ефремов Г. Д., Михайленко Д. С., Григорьева М. В., Войтко Д. А., и др. PCA3 и TMPRSS2-ERG в диагностике РПЖ: первый опыт применения комбинации маркеров в России. Экспериментальная и клиническая урология 2015;2:30−36.
• 42. Gilbert S.M., Cavallo C.B., Kahane H., Lowe F.C. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005;65(3):549−553.